^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bortezomib

    i
    Other names: LDP 341, MG 341, MLN 341, NSC 681239, PS 341, JNJ-26866138, PS-341, PS 0341, PS0341, NSC681239, LDP-341, PS341, LDP341, MLN341, MLN-341, NSC-681239
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    1d
    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    1d
    GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, PETHEMA Foundation
    New trial
    |
    B2M (Beta-2-microglobulin)
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    1d
    AB-HLA-2026: Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies (clinicaltrials.gov)
    P3, N=42, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P3 trial
    |
    bortezomib • Calquence (acalabrutinib)
    2d
    Proteasomal inhibition compromises microvascular integrity via distinct effects on non-immune endothelial cells and immune cells. (PubMed, Front Immunol)
    This indicates that although proteasomal inhibition is not inflammatory, TNF present in the microvascular environment synergizes with the drugs to compromise endothelial function. Our observations provide an explanation for how microvascular damage potentially underlies tissue injury driven by Bortezomib or Carfilzomib.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    bortezomib • carfilzomib
    5d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    5d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2025 --> Feb 2026
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    7d
    Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=720, Not yet recruiting, Dana-Farber Cancer Institute
    New P3 trial
    |
    TP53 (Tumor protein P53)
    |
    clonoSEQ®
    |
    bortezomib • dexamethasone • iberdomide (CC-220) • Lynozyfic (linvoseltamab-gcpt) • Sarclisa subcutaneous (isatuximab subcutaneous) • captisol-enabled melphalan
    7d
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 (clinicaltrials.gov)
    P3, N=255, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • pomalidomide
    7d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    7d
    Synergistic drug repurposing strategy identifies doxorubicin and paclitaxel as potential combination therapy for diffuse large B-cell lymphoma. (PubMed, Comput Biol Med)
    This integrative study highlights the therapeutic potential of Doxorubicin and Paclitaxel against DLBCL, supporting drug repurposing as a promising strategy for developing effective combinatorial therapies.
    Journal
    |
    TP53 (Tumor protein P53) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    sorafenib • paclitaxel • bortezomib • doxorubicin hydrochloride
    7d
    CAC-MM-001: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Oct 2025 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • SDC1 (Syndecan 1)
    |
    TP53 mutation
    |
    bortezomib
    7d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB | N=38 --> 153
    Enrollment change
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120